Navigation Links
MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Date:9/29/2010

ffers to buy any securities of MAP Pharmaceuticals and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The Company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the conduct and completion of clinical trials, and relating to the preparation and filing of a New Drug Application and the regulatory process to have the Company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent o
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PORTLAND, Oregon , August 28, 2014 /PRNewswire/ ... Market Research titled, "DNA diagnostics Market (products, applications, ... Analysis, Trends, Opportunities, Growth and Forecast, 2013 - ... would reach $19 billion by 2020 registering a ... potential to provide accurate diagnosis and cost effectiveness ...
(Date:8/28/2014)...  In recognition of the increased risks that ... flu, pneumonia, shingles and other illnesses, CVS/pharmacy ® ... to be Senior Vaccination Month. Because people,s immune ... that adults ages 65 years and older stay ... and MinuteClinic nurse practitioners and physician assistants will ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... Asia-Pacific Markets to 2020 - Novel ... in Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics ...
Breaking Medicine Technology:DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... Ph.D., will join the executive committee of Eli Lilly and ... Walsh will continue in her current role as Lilly,s ... Ph.D., chairman, president, and CEO, and working to ensure Lilly ... Walsh is a recognized thought leader in the ...
... June 30, 2011 Xlumena, Inc., a ... and endoscopic surgeon, announced today that it has received ... The NAVIX is a multi-function system that enables exchange-free ... endoscopic pancreatic pseudocyst drainage.  The NAVIX will join the ...
Cached Medicine Technology:Lilly Quality Leader Walsh Appointed to Company's Executive Committee 2Xlumena Receives CE Mark for NAVIX™, Second Product to Enter European Market 2
(Date:8/29/2014)... The Fresh Diet, America’s premier gourmet meal ... Vegetarian meal plan. Originating from The Fresh Diet’s commitment ... is designed to satisfy customers seeking a convenient, worry-free ... Responding to the growing demand by customers for non-meat ... (Forbes) with 14% of Americans identifying vegetarian meals as ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- The main strain ... Middle East and North Africa originated in sub-Saharan ... so-called community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) ... not recently been hospitalized. These infections typically affect ... contact or through touching contaminated objects such as ...
(Date:8/29/2014)... Parker Waichman LLP, a national law ... rights of victims who have been injured by medications ... new regulations for all hydrocodone combination products. According to ... dated August 21, 2014, the DEA will be regulating ... law. , The long-awaited announcement comes after a ...
(Date:8/29/2014)... 2014 TayganPoint Consulting Group, a leading ... second time, Inc. Magazine has named the company one ... Based on solid revenue growth of over 166% over ... on the list. TayganPoint’s repeat success in this ... past few years, is a demonstration of its strong ...
(Date:8/29/2014)... 2014 Gwyneth Paltrow, Beyonce and Angelina Jolie ... have inspired dieters all over the United States, to find ... to help them quickly shed excess fat. And, recent inspiration ... that substitutes all gluten products, eggs and meats for ingredients ... associated with following this type of diet, one must be ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 3Health News:Diet Doc Announces Diet Plans that Deliver Fast Weight Loss Results at a Fraction of the Cost of Celebrity Diets 2Health News:Diet Doc Announces Diet Plans that Deliver Fast Weight Loss Results at a Fraction of the Cost of Celebrity Diets 3
... Migraine is a neurovascular disease that affects about ... and beverages (chocolate, wine, citrus, etc) considered as ... and phenolic compounds. Avoiding those triggers may ... patients. However, only a small percentage ...
... reduce the use of mechanical ventilation with premature infants ... can profoundly affect those children,s outcomes while reducing the ... at Children,s Hospital Boston. The team, led ... Medicine at Children,s Hospital Boston and the Neonatal Intensive ...
... The American Association for Cancer Research is pleased to ... their families and caregivers won first place in ... of Colon and Rectal Surgeons. Separately, it received three ... the Society of Professional Journalists. "We are ...
... Daytime sleepiness may affect inhibitory control in the ... research abstract that will be presented Monday, June ... 25th Anniversary Meeting of the Associated Professional Sleep ... daytime sleepiness was associated with decreased activation in ...
... insomnia may be able to find relief by wearing a ... abstract that will be presented Monday, June 13, in Minneapolis, ... Associated Professional Sleep Societies LLC (APSS). According to the ... occurs while falling asleep and is associated with restorative sleep. ...
... Multiple Sclerosis sufferers emotional support through group therapy sessions ... NHS almost 500 per patient, a study at The ... planning a larger multi-centre study into the issue to ... MS services currently provided by the NHS. The ...
Cached Medicine News:Health News:The association of alcohol drinking with migraine headache 2Health News:Guidelines for ventilator use help premature infants breathe easier 2Health News:AACR's CR magazine honored with 4 prestigious journalism awards 2Health News:Sleepiness may impair the brain's inhibitory control when viewing high-calorie foods 2Health News:Cooling the brain during sleep may be a natural and effective treatment for insomnia 2Health News:Cooling the brain during sleep may be a natural and effective treatment for insomnia 3Health News:Group therapy helps MS sufferers cope with depression, study finds 2Health News:Group therapy helps MS sufferers cope with depression, study finds 3
... is the least expensive of the series. It has ... central area of the cornea. The model comes with ... a picture of a patients corneal endothelium, you simply ... on the chin rest. The left side of the ...
... The JSZ Orthokeratology (oprifocon ... gas permeable contact lenses used ... temporarily corrects nearsightedness (myopia). The ... and removes them in the ...
... contact lenses used for corneal refractive therapy, ... The patient wears the lenses overnight while ... the day, nearsightedness is corrected or greatly ... contact lenses apply slight pressure to the ...
... Looking for a way to help your ... cardiovascular disease? Based on the outcomes ... Counterpulsation (ECP) has improved the quality of ... perform normal activities of daily living. , ...
Medicine Products: